UNEXPECTED MOBILISATION OF LEAD DURING CISPLATIN CHEMOTHERAPY
Authors:
- A.M. El-SharkawiAEA.M. El-Sharkawi
- S. CobboldSCS. Cobbold
- C.J. EvansCEC.J. Evans
- D.R. ChettleDCD.R. Chettle
- W.D. MorganWMW.D. Morgan
- M.B.M. JaibMJM.B.M. Jaib
- L.J. SomervailleLSL.J. Somervaille
- M.C. ScottMSM.C. Scott
- 1 August 1986
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 328 (8501) , 249-250
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Anticancer drug pharmacodynamicsCancer Chemotherapy and Pharmacology, 1985
- In vivoX-ray fluorescence estimation of bone lead concentrations in Queensland adultsBritish Journal of Radiology, 1984
- Polarised x-rays in XRF-analysis for improved in vivo detectability of cadmium in manPhysics in Medicine & Biology, 1983
- An x-ray fluorescence technique to measure the mercury burden of dentists in vivoMedical Physics, 1981
- Feasibility Study for the in Vivo Measurement of Lead in Bone Using L-X-Ray FluorescenceIEEE Transactions on Nuclear Science, 1981
- Cisplatin (cis-diamminedichloroplatinum II)Cancer Treatment Reviews, 1979
- Cis-diamminedichloroplatinum (II)Annals of Internal Medicine, 1977
- Occupational lead nephropathyThe American Journal of Medicine, 1975
- Lead Metabolism in the Normal Human: Stable Isotope StudiesScience, 1973
- Platinum Compounds: a New Class of Potent Antitumour AgentsNature, 1969